Chemoembolization of liver cancer with drug-loading microsphere 50-100μm.
Chemoembolization of liver cancer with drug-loading microsphere 50-100μm.
复制标题
载药微球50-100μm化疗栓塞肝癌
DOI：
10.18632/oncotarget.14281
复制
发表时间：
2017-01-17
期刊：
影响因子：
--
通讯作者：
Zheng SS
中科院分区：
文献类型：
--
作者：
Sun JH;Zhou GH;Zhang YL;Nie CH;Zhou TY;Ai J;Zhu TY;Wang WL;Zheng SS
经导管动脉化疗栓塞术（TACE）是治疗不能切除的肝细胞癌（HCC）的主要手段。传统肝动脉化疗栓塞术（cTACE）治疗肝转移瘤的疗效不理想，这可能与栓塞材料的使用有关。近年来，HepaSphere作为一种新型载药微球已被引入中国。在本研究中，共有30例肝癌患者（18例男性和12例女性）接受了Hepasphere微球栓塞。使用50-100μm HepaSphere共进行了44例TACE手术。16例患者诊断为HCC，14例患者诊断为肝转移。随访时间3 ~ 15个月（中位10个月）。根据意向治疗计算缓解率。TACE后1个月，总客观缓解率为63.3%，疾病控制率为86.7%。无感染、肝脓肿、腹腔出血、肿瘤破裂等严重并发症。总之，Hepasphere微球化疗栓塞对肝癌患者可能是一种安全有效的姑息治疗。
Transcatheter arterial chemoembolization (TACE) is the mainstay of treatment for unresectable hepatocellular carcinoma (HCC). The efficacy of conventional TACE (cTACE) in liver metastases is not satisfactory, which might be due to the fact of embolic material used. Recently, as a new type of drug-loading microsphere, HepaSphere has been introduced in China. In this study, there were total 30 patients (18 males and 12 females) with liver cancer underwent embolization with Hepasphere microsphere. And a total of 44 TACE procedures were performed using 50-100μm HepaSphere. There were 16 patients diagnosed as HCC and 14 patients as liver metastases. The follow up period ranged from 3 to 15 months (median 10 months). Response rates were calculated on intention-to-treat basis. One month after TACE, total objective response was 63.3% and disease control rate was 86.7%. No severe complication (such as infection, liver abscess, abdominal bleeding, tumor rupture) was observed. In conclusion, chemoembolization with Hepasphere microsphere may be a safe and possibly effective palliative treatment for patients with liver cancer.